Lifesci Capital Brokers Lower Earnings Estimates for Abivax

Abivax SA Sponsored ADR (NASDAQ:ABVX) – Research analysts at Lifesci Capital reduced their FY2025 EPS estimates for Abivax in a research note issued to investors on Thursday, January 8th. Lifesci Capital analyst S. Slutsky now forecasts that the company will earn ($5.23) per share for the year, down from their previous estimate of ($3.47). The consensus estimate for Abivax’s current full-year earnings is ($2.83) per share.

Abivax (NASDAQ:ABVX) last released its quarterly earnings results on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The company had revenue of ($4.92) million for the quarter.

A number of other equities research analysts have also weighed in on ABVX. Oppenheimer set a $131.00 price objective on Abivax in a research note on Thursday. JMP Securities increased their target price on Abivax from $95.00 to $114.00 and gave the company a “market outperform” rating in a research note on Thursday, September 25th. BTIG Research increased their price objective on shares of Abivax from $120.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday. Wall Street Zen downgraded shares of Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Finally, Wolfe Research upgraded shares of Abivax to a “strong-buy” rating in a research note on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $135.08.

Abivax Stock Up 3.1%

Shares of Abivax stock opened at $118.00 on Monday. Abivax has a 1-year low of $4.77 and a 1-year high of $148.83. The company has a market capitalization of $9.20 billion, a PE ratio of -28.23 and a beta of 0.68. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86. The business has a 50-day moving average of $120.55 and a 200-day moving average of $86.42.

Institutional Investors Weigh In On Abivax

A number of hedge funds have recently bought and sold shares of the company. EverSource Wealth Advisors LLC grew its holdings in Abivax by 4,612.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after buying an additional 369 shares during the last quarter. First Horizon Corp acquired a new position in shares of Abivax during the third quarter valued at about $36,000. Bank of America Corp DE lifted its stake in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after buying an additional 1,990 shares during the period. Hantz Financial Services Inc. acquired a new stake in Abivax during the third quarter worth about $52,000. Finally, Cubist Systematic Strategies LLC increased its stake in Abivax by 34.3% during the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock valued at $63,000 after acquiring an additional 2,595 shares during the period. 47.91% of the stock is currently owned by institutional investors.

Key Headlines Impacting Abivax

Here are the key news stories impacting Abivax this week:

• Positive Sentiment: M&A/takeover reports reignited buying interest — multiple outlets reported Eli Lilly interest and a potential multi‑billion euro/dollar bid, driving strong upside momentum. Article Title
• Positive Sentiment: Major business press coverage amplified the story — Wall Street Journal and Reuters reported renewed M&A chatter, increasing visibility to institutional buyers and traders. Article Title Article Title
• Positive Sentiment: Analyst/upside notes and a raised price target support optimism — at least one outlet reported a higher price target, which can validate speculative bids and attract momentum buyers. Article Title
• Neutral Sentiment: Fundamentals remain a core bullish argument — Seeking Alpha highlights obefazimod’s strong ulcerative colitis data and multiple 2026 clinical/regulatory catalysts (Phase 3 topline, potential filing paths) that make Abivax an M&A target independent of rumor. Article Title
• Neutral Sentiment: Some analyst coverage/notes provide broader context but no clear directional change — a roundup piece discusses analyst views; interpret as background rather than a fresh catalyst. Article Title
• Neutral Sentiment: Data feed anomaly on short‑interest reporting — one entry shows 0 shares (NaN change), which appears to be an error and should be treated cautiously by traders. (internal data entry)
• Negative Sentiment: Official denial from French authorities tempers takeover certainty — France’s finance ministry said it has received no request for investment approval and no contact with Eli Lilly, which may reduce the probability or timing of any deal. Article Title
• Negative Sentiment: Analyst earnings revisions are mixed/negative — Lifesci Capital cut earnings estimates, which could be used by skeptics to argue the stock is overvalued absent a deal. Article Title
• Negative Sentiment: Elevated short interest from late December (≈2.9M shares, ~3.7% of float) signals significant bearish positioning that could add selling pressure or fuel short‑squeeze dynamics when headlines move. (internal data)

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.